Pharmacovigilance – Products
Comprehensive Characterization of O-Linked Glycosylation in Etanercept by Electron Activated Dissociation
Glycosylation is a common post-translational modification (PTM) that plays a critical role in antibody effector functions. Comprehensive characterization of N- and O-linked glycosylation in protein therapeutics is essential for ensuring drug safety and efficacy.
PerkinElmer’s Oxford Immunotec Receives U.S. FDA Approval for T-Cell Select To Automate Clinically Superior Tuberculosis Detection
PerkinElmer’s Oxford Immunotec has announced the U.S. Food and Drug Administration has approved the use of the T-Cell Select™ reagent kit for the automation of its T-SPOT®.TB test workflow for in vitro diagnostic use by certified laboratories.
Molecular Devices and HeartBeat.bio Announce Collaboration To Automate and Scale Cardiac Organoids
Molecular Devices, LLC. and HeartBeat.bio AG, a biotech company developing cardiac organoids for drug discovery, have entered into a co-development agreement.
SonALAsense Forges Ahead With First Patient Dosing for Devastating Childhood Brain Cancer
Multisite study will test sonodynamic therapy in pediatric patients with diffuse intrinsic pontine glioma (DIPG).
Voltron Therapeutics, Inc. Announces Definitive Proof of Concept Data for its Lead Oncology Candidate
Voltron Therapeutics, Inc. has announced that data from the previously announced Study ‘098 demonstrated clear Proof-of Concept for VTX-067 in the treatment of HPV-related cancers.
Epilepsy Patients Set To Benefit From Non-Invasive, Real-Time Molecular Breath Analysis
Deep Breath Intelligence is pleased to announce the launch of a simple breath test that can provide reliable estimates of circulating concentrations of the antiseizure medication valproic acid to aid patient management.
VectorBuilder To Invest $30 Million To Build the World’s First "AAV Superbank"
VectorBuilder Inc. has announced its plan to invest $30 million to build an "AAV Superbank" for the research and drug discovery community.
Avacta Announces Second Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-Doxorubicin
Avacta Group plc announces that the first-in-human Phase I trial of AVA6000 Pro-doxorubicin will advance to the third dose cohort following a positive review of the safety data from the dosing of the second cohort.
Precision BioSciences Provides Update on Allogeneic CAR T Programs and Path Forward With its Lead PBCAR0191 Candidate for CAR T Relapsed Patient Population
Precision BioSciences, Inc., has announced its latest program updates across its allogeneic CAR T pipeline.
Waters Introduces High Resolution Mass Spectrometry Products and Software To Accelerate Drug Development
Waters Corporation has unveiled new instruments, software and product enhancements to drive drug discovery and development at the American Society for Mass Spectrometry 2022 Annual Conference.